{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T08:22:17Z","timestamp":1794558137134,"version":"4.9.1"},"reference-count":23,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2007,12,7]],"date-time":"2007-12-07T00:00:00Z","timestamp":1196985600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2008,4]]},"abstract":"<jats:sec><jats:label\/><jats:p> <jats:bold>What is already known about this subject<\/jats:bold> <\/jats:p><jats:p>\u2022\u2002Although drugs generally are safe and effective therapies for numerous diseases, adverse drug reactions do occur and may even be fatal.<\/jats:p><jats:p>\u2022\u2002The incidence of fatal adverse drug reactions in hospitalized patients has been estimated to be approximately 5%.<\/jats:p><jats:p>\u2022\u2002In previous studies the incidence of fatal adverse drug reactions in hospitalized patients has been reported, but the incidence of fatal adverse drug reactions in the general population is largely unknown.<\/jats:p><jats:p> <jats:bold>What this study adds<\/jats:bold> <\/jats:p><jats:p>\u2022\u2002Fatal adverse drug reactions account for approximately 3% of all deaths in the general population.<\/jats:p><jats:p>\u2022\u2002Haemorrhages amount to almost two\u2010thirds of the fatal adverse drug reactions and antithrombotic agents are implicated in more than half of the suspected fatal adverse drug reactions.<\/jats:p><jats:p>\u2022\u2002Fatal adverse drug reactions are estimated to be the seventh most common cause of death in Sweden.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aims<\/jats:title><jats:p>To determine the incidence of fatal adverse drug reactions (FADRs) in a Swedish population.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Every seventh randomly selected deceased in three counties in South\u2010east Sweden during 1 January 2001\u201331 December 2001 was identified in the Cause of Death Register. Relevant case records (hospitals and\/or primary care centres and medicolegal files) were reviewed to identify suspected drug\u2010related fatalities.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of 1574 deceased study subjects, 49 (3.1%; 95% CI 2.2%, 4.0%) were suspected to have died from FADRs. The most common suspected FADRs were gastrointestinal haemorrhages (<jats:italic>n<\/jats:italic>\u2003=\u200318; 37%), central nervous system haemorrhages (<jats:italic>n<\/jats:italic>\u2003=\u200314; 29%), cardiovascular disorders (<jats:italic>n<\/jats:italic>\u2003=\u20035; 10%), other haemorrhages (<jats:italic>n<\/jats:italic>\u2003=\u20034; 8%) and renal dysfunction (<jats:italic>n<\/jats:italic>\u2003=\u20033; 6%). The drugs most commonly implicated in FADRs were antithrombotic drugs (<jats:italic>n<\/jats:italic>\u2003=\u200331; 63%), followed by nonsteroidal anti\u2010inflammatory drugs (NSAIDs) (<jats:italic>n<\/jats:italic>\u2003=\u20039; 18%), antidepressants (<jats:italic>n<\/jats:italic>\u2003=\u20037; 14%) and cardiovascular drugs (<jats:italic>n<\/jats:italic>\u2003=\u20034; 8%). Of all the 639 fatalities in hospital 41 (6.4%; 95% CI 4.5%, 8.3%) were suspected to be due to FADRs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The medical burden of FADRs is significant. Haemorrhages were seen in a majority of the FADRs; antithrombotic agents or NSAIDs were implicated in most of these events. These results suggest that preventive measures should be taken to reduce the number of deaths caused by drugs.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1365-2125.2007.03064.x","type":"journal-article","created":{"date-parts":[[2008,3,11]],"date-time":"2008-03-11T10:26:26Z","timestamp":1205231186000},"page":"573-579","source":"Crossref","is-referenced-by-count":239,"title":["Incidence of fatal adverse drug reactions: a population based study"],"prefix":"10.1111","volume":"65","author":[{"given":"Karin","family":"Wester","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna K.","family":"J\u00f6nsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olav","family":"Spigset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Druid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Staffan","family":"H\u00e4gg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2007,12,7]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-002-0467-0"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12266"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/pds.667"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.279.15.1200"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-002-0501-2"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.320.7241.1036"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002280000158"},{"key":"e_1_2_6_9_2","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1001\/jama.1977.03270360041015","article-title":"Drug\u2010related deaths among medical inpatients","volume":"237","author":"Porter J","year":"1977","journal-title":"JAMA"},{"key":"e_1_2_6_10_2","first-page":"350","article-title":"Adverse reporting on adverse reactions","volume":"160","author":"Bains N","year":"1999","journal-title":"CMAJ"},{"key":"e_1_2_6_11_2","unstructured":"World Health Organisation.Mortality Theme Issue: Glossary. Available athttp:\/\/www.who.International\/bulletin\/Volumes\/84\/3\/mortality_glossary\/en\/(last accessed: 30 May 2007)."},{"key":"e_1_2_6_12_2","unstructured":"World Health Organisation.International Drug Monitoring: the Role of National Centres. WHO Technical Report Series 1972 no. 498."},{"key":"e_1_2_6_13_2","unstructured":"World Health Organisation.Causality Assessment of Suspected Adverse Reactions. Available athttp:\/\/www.who\u2010umc.org\/DynPage.aspx?id=22682(last accessed: 24 November 2006)."},{"key":"e_1_2_6_14_2","first-page":"18","volume-title":"Davies's Textbook of Adverse Drug Reactions","author":"Rawlins MD","year":"1991"},{"key":"e_1_2_6_15_2","unstructured":"World Health Organisation Collaborating Centre for International Drug Monitoring.Adverse reaction terminology. 31 December 1991."},{"key":"e_1_2_6_16_2","unstructured":"The National Board of Health and Welfare Centre for Epidemiology.Causes of Death 2001. Available athttp:\/\/www.socialstyrelsen.se(last accessed: 30 May 2007)."},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(00)00460-5"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1263"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2005-916670"},{"key":"e_1_2_6_20_2","volume-title":"Farmacevtiska specialiteter i Sverige 2006 (FASS 2006) (Pharmaceutical Specialities in Sweden\u2010Swedish Physicians Desk Reference)","author":"L\u00e4kemedelsindustrif\u00f6reningen, LIF (The Swedish Association of the Pharmaceutical Industry).","year":"2006"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.324.7329.71"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-131-7-199910050-00003"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002280050314"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(02)00450-X"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2125.2007.03064.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2125.2007.03064.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T01:13:08Z","timestamp":1697418788000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2125.2007.03064.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,12,7]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2008,4]]}},"alternative-id":["10.1111\/j.1365-2125.2007.03064.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2125.2007.03064.x","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,12,7]]}}}